BSF Enterprise PLC (LSE:BSFA, OTC:BSFAF) lost ground on Tuesday after a debt conversion sparked equity dilution concerns across its shareholder base.
The tissue engineering, lab-grown materials, and bioactive solutions developer fell 10.56% to 1.12p in morning London trade as the market absorbed the planned arrival of new shares.
At the heart of the decline is a formal conversion notice from Indigo Capital Investments regarding the company's £1 million convertible loan note instrument.
That notice requires the business to issue 10,000,000 new ordinary shares of 1 penny each to satisfy £100,283 of the outstanding debt balance.
Compounding the dilution pressure, the group confirmed that an application will be made for the new shares to enter the Equity Shares transition category of the Official List.
Official admission and dealings on the London Stock Exchange's main market for listed securities are scheduled to become effective at 8.00 a.m. on 28 August 2026.
The new equity will rank equally in all respects with existing stock, expanding the company's issued share capital and total voting rights to 203,749,437 ordinary shares.
In its regulatory disclosure, the group confirmed that the market filing contained inside information under domestic market abuse legislation.
Hanging over any near-term share price recovery is the remaining £899,717 debt balance under the loan facility, which carries the continuing risk of further equity dilution if converted.
